title: Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo.
abstract: To investigate the effect of haloperidol (HAL) on second messengers in the brain striatum, the concentrations of cAMP and inositol trisphosphate (IP-3) were measured in the striatum of rats in vivo after intravenous administration of HAL, and their concentrations were compared with the severity of catalepsy and changes in dopamine (DA) metabolism in the striatum. Catalepsy developed both in the animals treated with 5 mg/kg and those with 0.5 mg/kg of HAL, but it appeared earlier, and the period of severe catalepsy was longer in the former than in the latter. In the animals treated with 5 mg/kg of HAL, DOPAC and HVA began to increase at 20 min after administration, and their percent increases were correlated with the severity of catalepsy. In the 5 mg/kg animals, both cAMP and IP-3 increased. The IP-3 showed a delayed peak but a greater increase as compared with the cAMP. In the 0.5 mg/kg animals, only IP-3 increased. These findings suggest that HAL might affect not only the adenylate cyclase system but also the phosphoinositide response in the striatum. Moreover, the changes in the phosphoinositide response might be secondarily induced by the blocking of D-2 receptors by HAL.
authors.affiliation: Department of Neuropsychiatry, Fukushima Medical College, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kaneko
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: R
authors.initials: R
authors.lastname: Horikoshi
authors.forename: M
authors.initials: M
authors.lastname: Yaginuma
authors.forename: N
authors.initials: N
authors.lastname: Yaginuma
authors.forename: M
authors.initials: M
authors.lastname: Shiragata
authors.forename: H
authors.initials: H
authors.lastname: Kumashiro
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002375:Catalepsy / Q000139:chemically induced / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology* / Q000633:toxicity; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects; D015290:Second Messenger Systems / Q000187:drug effects*
chemical_list: D011954:Receptors, Dopamine; D015102:3,4-Dihydroxyphenylacetic Acid; D006897:Hydroxyindoleacetic Acid; D015544:Inositol 1,4,5-Trisphosphate; D000242:Cyclic AMP; D006220:Haloperidol; D004298:Dopamine; D006719:Homovanillic Acid